Table 1

Suggested vaccines for adult people with MS

VaccineTypeScheduleRecommendation in MS
Boostrix-IPVDiphtheria, tetanus, pertussis (acellular) and polio (inactivated)Single intramuscular dose any time from 16 weeks up to 32 weeks of pregnancyPregnant women with MS
GardasilHuman papillomavirus 6, 11, 16 and 18 (recombinant)3 intramuscular doses at months 0, 2 and 6. All three doses should be given within a 1-year periodPeople with MS aged ≤25 years who are unimmunised or partially immunised against human papillomavirus
Gardasil 9Human papillomavirus 6, 11, 16, 18, 31, 33, 45, 52 and 58 (recombinant)3 intramuscular doses at months 0, 2 and 6. All three doses should be given within a 1-year periodPeople with MS aged ≤25 years who are unimmunised or partially immunised against human papillomavirus
Trivalent influenza vaccineInfluenza virus (inactivated)Single intramuscular dose every yearPeople with MS aged ≥65 years
Quadrivalent influenza vaccineInfluenza virus (inactivated)Single intramuscular/SC dose every yearPeople with MS aged <65 years (including pregnant women with MS)
Pneumococcal polysaccharide vaccinePneumococcus (polysaccharide)Single intramuscular/SC dosePeople with MS aged ≥65 years. Also, regardless of age: patients who anticipate long-term immunosuppression and for those with compromised pulmonary function or high levels of disability (EDSS ≥7)
Priorix or M-M-RvaxProMMR vaccines (live-attenuated vaccine)*2 intramuscular/SC doses given 4 weeks apartPeople with MS who are susceptible to primary MMR infections
VarilrixVZV (live-attenuated vaccine)*2 SC doses given 6 weeks apartPeople with MS who are susceptible to primary VZV infection
VarivaxVZV (live-attenuated vaccine)*2 intramuscular/SC doses given 4–8 weeks apartPeople with MS who are susceptible to primary VZV infection
ZostavaxVZV (live-attenuated vaccine)*Single intramuscular/SC dosePrevention of herpes zoster and postherpetic neuralgia in people with MS aged 70–79 years**
ShingrixVZV (recombinant)2 intramuscular doses separated by 2–6 monthsPrevention of herpes zoster and postherpetic neuralgia in people with MS aged ≥50 years
  • *This vaccine should not be given to people who are already on an immunosuppressive disease-modifying therapy.

  • **Zostavax is licensed for immunisation of people aged ≥50 years and can be used outside of the national immunisation programme based on clinical discretion.

  • EDSS, Expanded Disability Status Scale; MMR, measles, mumps and rubella; MS, multiple sclerosis; SC: subcutaneous; VZV, varicella-zoster virus.